Treg-enriched allogeneic haematopoietic stem cell graft

Class

Precision-engineered allogeneic hematopoietic stem cell graft with a defined T-cell subset composition (immune-tolerant Treg-enriched, conventional T-cell-limited graft) for allogeneic HSCT

Pathway

Graft T-cell subset ratio control to reduce graft-versus-host disease while preserving graft-versus-leukemia effect, without post-transplant pharmacologic immunosuppression

This mechanism concerns a cell therapy product used in allogeneic hematopoietic stem cell transplantation (HSCT), the procedure by which blood-forming stem cells from a donor are given to a recipient, usually to treat blood cancers or serious blood disorders. A standard donor graft contains stem cells plus various T lymphocytes. These T cells are a double-edged sword: some recognize residual cancer cells and help eliminate them (the graft-versus-leukemia effect), while others recognize the recipient's own healthy tissues as foreign and attack them, causing graft-versus-host disease (GVHD), a major cause of illness and death after transplant. This approach engineers the graft's T-cell composition directly, enriching it in regulatory T cells (Tregs), which dampen unwanted immune attack, while limiting conventional T cells, which are more likely to drive tissue damage. The biological rationale is to preserve the cancer-fighting benefit of donor T cells while reducing the harmful autoimmune-like reaction, ideally without relying on standard post-transplant immunosuppressive drugs, which carry their own toxicities and infection risks. This mechanism is broadly relevant to any condition treated with allogeneic HSCT, including leukemias, lymphomas, and certain non-malignant blood and immune disorders, where balancing tolerance and anti-tumor immunity determines both survival and quality of life after transplant.